Claims for Patent: 10,981,923

Summary for Patent: 10,981,923

Title:	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2- -trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Abstract:	The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-- trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Inventor(s):	Allian; Ayman (Newbury Park, CA), Borchardt; Thomas B. (Kenosha, WI), Jayanth; Jayanthy (Buffalo Grove, IL), Marroum; Patrick J. (Springfield, VA), Mayer; Peter T. (Libertyville, IL), Mulhern; Mathew M. (Lake Villa, IL), Nordstrom; Fredrik Lars (Ridgefield, CT), Sheikh; Ahmad Y. (Lake Forest, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	16/905,667
Patent Claims:	1. Crystalline (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-- trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) selected from the group consisting of: a. crystalline freebase Compound 1 having an X-ray powder diffraction pattern characterized by peaks at 7.9.+-.0.2, 10.3.+-.0.2, and 13.4.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic Kai radiation; b. crystalline freebase Compound 1 having an X-ray powder diffraction pattern characterized by peaks at 9.7.+-.0.2, 14.2.+-.0.2, and 20.3.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic Kai radiation; and c. crystalline tartrate Compound 1 having an X-ray powder diffraction pattern characterized by peaks at 3.9.+-.0.2, 14.1.+-.0.2, and 15.7.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation. 2. A solid composition comprising a solid state form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-- trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1), wherein at least about 80% by weight of the solid state form is an amorphous freebase of Compound 1. 3. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier and an amorphous freebase of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-- trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1), comprising contacting a crystalline freebase of Compound 1 with the pharmaceutically acceptable carrier, wherein crystalline freebase of Compound 1 is converted into amorphous freebase of Compound 1. 4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amorphous freebase of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-- trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1), prepared by the process of claim 3. 5. The crystalline freebase Compound 1 of claim 1, having an X-ray powder diffraction pattern characterized by peaks at 7.9.+-.0.2, 10.3.+-.0.2, and 13.4.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation. 6. The crystalline freebase Compound 1 of claim 5, having an X-ray powder diffraction pattern characterized by peaks at 7.9.+-.0.2, 10.3.+-.0.2, and 13.4.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation, and further characterized by at least one additional peak selected from the group consisting of 15.1.+-.0.2, 15.5.+-.0.2, 17.0.+-.0.2, 17.2.+-.0.2, 18.3.+-.0.2, 19.3.+-.0.2, 20.5.+-.0.2, 20.9.+-.0.2, 21.7.+-.0.2, 21.9.+-.0.2, and 24.9.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation. 7. The crystalline freebase Compound 1 of claim 5, which is a hemihydrate. 8. The crystalline freebase Compound 1 of claim 1, having an X-ray powder diffraction pattern characterized by peaks at 9.7.+-.0.2, 14.2.+-.0.2, and 20.3.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation. 9. The crystalline freebase Compound 1 of claim 8, having an X-ray powder diffraction pattern characterized by peaks at 9.7.+-.0.2, 14.2.+-.0.2, and 20.3.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation, and further characterized by at least one additional peak selected from the group consisting of 8.0.+-.0.2, 14.5.+-.0.2, 23.0.+-.0.2, and 24.7.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation. 10. The crystalline freebase Compound 1 of claim 8, which is an anhydrate. 11. The crystalline tartrate Compound 1 of claim 1, having an X-ray powder diffraction pattern characterized by peaks at 3.9.+-.0.2, 14.1.+-.0.2, and 15.7.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation, wherein the crystalline tartrate Compound 1 is a tetrahydrate. 12. The crystalline tartrate Compound 1 of claim 1, having an X-ray powder diffraction pattern characterized by peaks at 3.9.+-.0.2, 14.1.+-.0.2, and 15.7.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation, and further characterized by at least one additional peak selected from the group consisting of 6.8.+-.0.2, 11.8.+-.0.2, 18.0.+-.0.2, 21.9.+-.0.2, and 25.9.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation. 13. The crystalline tartrate Compound 1 of claim 12, which is a tetrahydrate. 14. The composition of claim 2, wherein the amorphous freebase comprises blade or irregular morphology. 15. The composition of claim 14, wherein the blade morphology comprises hexagonal crystal faces. 16. The composition of claim 2, further comprising tartartic acid. 17. The composition of claim 2, wherein at least about 98% by weight of the solid state form is the amorphous freebase of Compound 1. 18. The composition of claim 2, wherein the composition comprises the solid state form dispersed in a hydrophilic polymer. 19. The composition of claim 2, wherein the amorphous freebase of Compound 1 in the composition exhibits no growth of degradation products after storage at 50.degree. C. and 75% relative humidity in an open or closed glass vial for at least six weeks. 20. The process of claim 3, wherein the contacting comprises dispersing the crystalline freebase of Compound 1 in the pharmaceutically acceptable carrier. 21. The process of claim 3, wherein the pharmaceutically acceptable carrier is a hydrophilic polymer. 22. The process of claim 3, wherein at least about 80% by weight of crystalline freebase of Compound 1 is converted into amorphous freebase of Compound 1. 23. The process of claim 3, wherein at least about 98% by weight of crystalline freebase of Compound 1 is converted into amorphous freebase of Compound 1. 24. The process of claim 3, wherein the crystalline freebase of Compound 1 is selected from the group consisting of: a. crystalline freebase Compound 1 having an X-ray powder diffraction pattern characterized by peaks at 7.9.+-.0.2, 10.3.+-.0.2, and 13.4.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation; b. crystalline freebase Compound 1 having an X-ray powder diffraction pattern characterized by peaks at 9.7.+-.0.2, 14.2.+-.0.2, and 20.3.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation; and c. crystalline tartrate Compound 1 having an X-ray powder diffraction pattern characterized by peaks at 3.9.+-.0.2, 14.1.+-.0.2, and 15.7.+-.0.2 degrees two theta when measured at about 25.degree. C. with monochromatic K.alpha.1 radiation. 25. The pharmaceutical composition of claim 4, comprising a dispersion of the amorphous freebase of Compound 1 in the pharmaceutically acceptable carrier. 26. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable carrier is a hydrophilic polymer. 27. The pharmaceutical composition of claim 4, wherein at least about 80% by weight of the Compound 1 present in the composition is the amorphous freebase of Compound 1. 28. The pharmaceutical composition of claim 4, wherein at least about 98% by weight of the Compound 1 present in the composition is the amorphous freebase of Compound 1. 29. The pharmaceutical composition of claim 25, wherein at least about 80% by weight of the Compound 1 present in the composition is the amorphous freebase of Compound 1. 30. The pharmaceutical composition of claim 25, wherein at least about 98% by weight of the Compound 1 present in the composition is the amorphous freebase of Compound 1.